Sansera Engineering signs Rs 160 crore contract with Airbus to manufacture critical airborne medical modules
By Aditya Bhagchandani Published on June 3, 2025, 14:30 IST
Sansera Engineering Limited has announced a significant milestone in its aerospace journey, securing a long-term contract valued at approximately Rs 160 crore (USD 18.8 million) with Airbus Defence and Space. Under this agreement, Sansera will be responsible for the manufacture, supply, and support of the Airborne Intensive Care Transport Module (ICTM), a specialized medical evacuation system designed for light and medium transport aircraft.
The ICTM is engineered to facilitate the air transport of patients in critical condition, including those needing intensive care support. This contract marks the first time Airbus has partnered with an Indian company for the manufacturing of the ICTM Kit.
Sansera will handle the precision machining and structural assembly of the modules at its Bengaluru facility. The partnership is seen as a strategic boost for India's growing role in the global aerospace and defence supply chain.
Commenting on the deal, Sansera's Chairman & MD, Mr. S Sekhar Vasan, said, 'This partnership not only elevates Sansera's position in the aerospace sector but also contributes to the Make in India initiative by enhancing local advanced manufacturing capabilities.'
Founded in 1981, Sansera Engineering has built a reputation for supplying complex precision components across both automotive and non-automotive sectors. This includes key supplies to aerospace, defence, and semiconductor industries.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Fighter pilot takes next giant step for India's space plans
Astronaut Shubhanshu Shukla blasts off into space next week as the first Indian to join the International Space Station (ISS), bearing with him New Delhi's dreams of its own manned space flight. An airforce fighter pilot, 39-year-old Shukla is joining a four-crew mission launching from the United States with private company Axiom Space, aboard a SpaceX Crew Dragon capsule. He will become the first Indian to join the ISS, and only the second ever in orbit -- an achievement that the world's most populous nation hopes will be a stepping stone for its own human flight. "I truly believe that even though, as an individual, I am travelling to space, this is the journey of 1.4 billion people," Shukla was quoted as saying by The Hindu newspaper this year. Shukla said he hopes to "ignite the curiosity of an entire generation in my country", and "drive the innovation that will make many such projects possible for us in the future". The airforce group captain -- equivalent to an army colonel or navy captain -- will pilot the commercial mission slated to launch June 10 from the Kennedy Space Center in Florida, a joint team between NASA and ISRO, the Indian Space Research Organisation. - 'New era' - India's Department of Space calls it a "defining chapter" in its ambitions, naming Shukla as "among the top contenders" for its maiden human spaceflight mission, Gaganyaan, "sky craft" in Hindi, scheduled for launch in 2027. "His journey is more than just a flight -- it's a signal that India is stepping boldly into a new era of space exploration," the Department of Space said ahead of the launch. New Delhi has paid more than $60 million for the mission, according to Indian media reports. Prime Minister Narendra Modi has announced plans to send a man to the Moon by 2040. India's ISRO said in May that it planned to launch an uncrewed orbital mission later this year, before its first human spaceflight in early 2027. Shukla's voyage comes four decades after Indian astronaut Rakesh Sharma joined a Russian Soyuz spacecraft in 1984. "What sets Shukla's mission apart is its strategic importance," the department added. "Unlike the symbolic undertones of India's first human spaceflight, this time the focus is on operational readiness and global integration." Shukla also trained in Russia, in 2020 along with three other astronaut hopefuls, at the Yuri Gagarin Cosmonaut Training Center -- before further training at ISRO's centre in the southern city of Bengaluru. He has said the journey aboard the Axiom Mission 4 -- and then the expected 14 days on the ISS -- will provide "invaluable" lessons to bring back home. - Space yoga - Shukla will be led by mission commander Peggy Whitson, a former NASA astronaut, and joined by European Space Agency project astronaut Slawosz Uznanski-Wisniewski of Poland, and Tibor Kapu of Hungary. The son of a government ministry official, from Lucknow in the northern state of Uttar Pradesh, Shukla is a veteran fighter pilot experienced in flying Russian Sukhoi and MiG jets. He has promised to perform yoga poses in the ISS. If he is unable to fly on Tuesday, fellow airforce pilot Group Captain Prasanth Balakrishnan Nair, 48, is expected to take his place. India has flexed its ambitions in the last decade with its space programme growing considerably in size and momentum, matching the achievements of established powers at a much cheaper price tag. In August 2023, it became just the fourth nation to land an unmanned craft on the Moon after Russia, the United States and China. Waiting at home will be Shukla's family, including his wife and son. "I've been having goosebumps by just thinking that soon my brother will be in space," his older sister Suchi, a school teacher, told the Times of India newspaper. abh/pjm/fox/sco
Yahoo
27 minutes ago
- Yahoo
Flex LNG - Ex Date Q1 2025
HAMILTON, Bermuda, June 5, 2025 /PRNewswire/ -- The shares in Flex LNG Ltd. (Ticker: FLNG) traded on Oslo Stock Exchange ("OSE") and registered with Euronext Securities Oslo will trade ex dividend of USD 0.75 per share as of today, June 5, 2025. The dividend will be paid to shareholders on OSE on or about June 25, 2025. The shares traded on the New York Stock Exchange ("NYSE") will be traded ex dividend of USD 0.75 per share on June 6, 2025. The dividend will be paid to shareholders on NYSE on or about June 20, 2025. For further information, please contact: Mr. Knut Traaholt, Chief Financial Officer of Flex LNG Management AS Telephone: +47 23 11 40 00Email: ir@ About Flex LNG Flex LNG is a shipping company focused on the growing market for Liquefied Natural Gas (LNG). Our fleet consists of thirteen LNG carriers on the water and all of our vessels are state-of-the-art ships with the latest generation two-stroke propulsion (MEGI and X-DF). These modern ships offer significant improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. Flex LNG is listed on the New York Stock Exchange as well as Oslo Stock Exchange under the ticker FLNG. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision View original content: SOURCE Flex LNG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year. David Veitch, Basilea's Chief Executive Officer, stated: 'This milestone payment for the Asia Pacific region, including China, reflects the strong and growing global demand for novel antifungal therapies. Continued growth of Cresemba, particularly in China, where uptake has been especially robust, reinforces its significant clinical value for patients facing life-threatening infections. We congratulate our partner Pfizer for their ongoing commitment to making Cresemba available to patients in need.' The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region. Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between January and December 2024 amounted to USD 562 million, a 19 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1 About Cresemba® (isavuconazole) Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This press release can be downloaded from References IQVIA Analytics Link, December 2024. In-market sales reported as moving annual total (MAT) in US dollar. European Public Assessment Report (EPAR) Cresemba: [Accessed: June 04, 2025] Summary of Product Characteristics (SmPC) Cresemba: [Accessed: June 04, 2025] Full US prescribing information: [Accessed: June 04, 2025] The registration status and approved indications may vary from country to country. Attachment Press release (PDF)
